- All patients with resectable CRLM without extrahepatic metastases confirmed by tissue
diagnosis or radiologic exam who are undergoing hepatic resection.
- All patients undergoing hepatic arterial infusion pump placement with or without
without hepatic resection.
- Patients may have synchronous or metachronous CRLM
- Patients may have received prior cytotoxic (must be off for at least 2 weeks prior to
surgery) or anti-angiogenic therapy (must be off for at least 6 weeks prior to
surgery). Specific drugs are listed below.
- 5-FU based chemotherapy - 2 weeks off
- Bevacizumab - 6 weeks off
- Cetuximab or panitumumab - 2 weeks off
- Control patients will include patients consented for pancreaticoduodenectomy for
benign or pre-neoplastic lesions. If lesions assumed to be benign turn out to be
malignant on final pathology, the blood will be discarded and the patient replaced.
- Evidence of extra-hepatic disease on pre-operative imaging or at operative
exploration, excluding the primary colorectal tumor
- Those with known bleeding or clotting diatheses
- Patients diagnosed with chronic inflammatory diseases such as lupus, rheumatoid
arthritis, psoriasis, ulcerative colitis, Crohns disease, etc.
- Pre- or intra-operative evidence of portal vein thrombosis or hypertension
- Patients who have taken immune modulating agents in the past 8 weeks including
steroids, anti-TNF-α, interferon etc. Patients taking a single dose of Decadron as
part of a chemotherapy regimen will not be excluded from the study.
- Patients who take daily anti-inflammatory medications such as COX-2 inhibitors or
high dose NSAIDs. Patients taking a daily aspirin or acetaminophen or occasional
anti-inflammatory medications will not be excluded from the study.
- If at the discretion of the operating surgeon, blood acquisition would lead to undue
morbidity, the patient will be excluded and replaced
- Attending physicians authorized to obtain informed consent may exercise discretion in
excluding individuals for appropriate medical or other reasons.